Bambusa Therapeutics BBTX Director · filings 2026 to 2026
No transactions in the filings read; Form 144 notices are listed above.
Person · CIK 1663427
Howard Liang
Director at Bambusa Therapeutics
Earlier: BeiGene
Sold on Form 4$48.8M
Noticed on Form 144$0
Bought on Form 4$120K
Companies2
Holdings now
As reported after the latest Form 3, 4 or 5 at each company.
How these figures work
Options and RSUs are from the latest filing that lists them; earlier grants may also be held. Holdings can be out of date when a person stops filing.
| Company | Security | Held | Shares or units | As of |
|---|---|---|---|---|
| Bambusa Therapeutics BBTX | Stock Option (right to buy) exercise $8.04, expires Jul 9, 2036, into Common Stock | Directly | 153,908 | Oct 29, 2026 · Filing · EDGAR |
| BeiGene | Ordinary Shares | Directly | 1,553,149 | Jun 28, 2021 · Filing · EDGAR |
| BeiGene | Amerian Depositary Shares | Directly | 5,000 | Mar 16, 2018 · Filing · EDGAR |
Sold and noticed by quarter
Sold (Form 4) Noticed (Form 144) Bought (Form 4)
Quarterly totals as a table
| Quarter | Sold (Form 4) | Noticed (Form 144) | Bought (Form 4) |
|---|---|---|---|
| Q2 2021 | $551K | Not machine-readable | — |
| Q1 2021 | $4.8M | Not machine-readable | — |
| Q4 2020 | $25.2M | Not machine-readable | — |
| Q3 2020 | $3.5M | Not machine-readable | — |
| Q2 2020 | $135K | Not machine-readable | — |
| Q4 2019 | $4.9M | Not machine-readable | — |
| Q2 2019 | $3.3M | Not machine-readable | — |
| Q1 2018 | $6.4M | Not machine-readable | — |
| Q1 2016 | — | — | $120K |
Form 144 notices went onto EDGAR as structured data on April 13, 2023. Earlier notices were filed on paper and cannot be read here, so those quarters show no noticed amount.
Planned sales (Form 144) and the sales that followed
Each Form 144 notice of a planned sale, grouped by broker and 10b5-1 plan, with the Form 4 sales we matched to it.
How we match
A Form 144 is a notice of a planned sale by an affiliate. SEC Tracker matches each notice to Form 4 sales by the same person at the same company within 90 days of the notice, up to the shares noticed. The match is our inference, not something either filing states.
No Form 144 notices with structured data (filed on EDGAR since April 2023).
| Notice date | Noticed | Planned sale | Outcome | Links |
|---|---|---|---|---|
| Sales without a matching Form 144 · 58 sales No matching Form 144 found. Not every sale needs one: small sales and sales by people who are not affiliates are exempt. | ||||
| — | — | — | Notice not machine-readable BeiGene: Sold 446 at $365.00 on Jun 28, 2021 · $163K | Filing · EDGAR |
| — | — | — | Notice not machine-readable BeiGene: Sold 486 at $325.89 on Jun 18, 2021 · $158K | Filing · EDGAR |
| — | — | — | Notice not machine-readable BeiGene: Sold 650 at $354.16 on Jun 7, 2021 · $230K | Filing · EDGAR |
| — | — | — | Notice not machine-readable BeiGene: Sold 5,606 at $345.54 on Jan 15, 2021 · $1.9M (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable BeiGene: Sold 6,994 at $344.38 on Jan 15, 2021 · $2.4M (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable BeiGene: Sold 300 at $345.15 on Jan 14, 2021 · $104K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable BeiGene: Sold 1,100 at $344.28 on Jan 14, 2021 · $379K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable BeiGene: Sold 700 at $232.19 on Dec 14, 2020 · $163K | Filing · EDGAR |
| — | — | — | Notice not machine-readable BeiGene: Sold 17,456 at $231.11 on Dec 14, 2020 · $4M | Filing · EDGAR |
| — | — | — | Notice not machine-readable BeiGene: Sold 24,842 at $230.51 on Dec 14, 2020 · $5.7M | Filing · EDGAR |
| — | — | — | Notice not machine-readable BeiGene: Sold 9,752 at $229.18 on Dec 14, 2020 · $2.2M | Filing · EDGAR |
| — | — | — | Notice not machine-readable BeiGene: Sold 5,885 at $228.23 on Dec 14, 2020 · $1.3M | Filing · EDGAR |
| — | — | — | Notice not machine-readable BeiGene: Sold 400 at $228.10 on Dec 14, 2020 · $91K | Filing · EDGAR |
| — | — | — | Notice not machine-readable BeiGene: Sold 7,500 at $227.72 on Dec 14, 2020 · $1.7M | Filing · EDGAR |
| — | — | — | Notice not machine-readable BeiGene: Sold 15,062 at $227.08 on Dec 14, 2020 · $3.4M | Filing · EDGAR |
| — | — | — | Notice not machine-readable BeiGene: Sold 6,203 at $226.40 on Dec 14, 2020 · $1.4M | Filing · EDGAR |
| — | — | — | Notice not machine-readable BeiGene: Sold 4,100 at $225.24 on Dec 14, 2020 · $923K | Filing · EDGAR |
| — | — | — | Notice not machine-readable BeiGene: Sold 300 at $304.15 on Oct 5, 2020 · $91K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable BeiGene: Sold 1,869 at $303.24 on Oct 5, 2020 · $567K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable BeiGene: Sold 2,831 at $302.11 on Oct 5, 2020 · $855K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable BeiGene: Sold 1,499 at $300.88 on Oct 5, 2020 · $451K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable BeiGene: Sold 2,001 at $300.08 on Oct 5, 2020 · $600K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable BeiGene: Sold 1,000 at $298.97 on Oct 5, 2020 · $299K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable BeiGene: Sold 1,200 at $297.98 on Oct 5, 2020 · $358K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable BeiGene: Sold 500 at $296.47 on Oct 5, 2020 · $148K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable BeiGene: Sold 568 at $295.73 on Oct 5, 2020 · $168K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable BeiGene: Sold 1,415 at $294.92 on Oct 5, 2020 · $417K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable BeiGene: Sold 817 at $293.26 on Oct 5, 2020 · $240K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable BeiGene: Sold 103 at $252.59 on Sep 14, 2020 · $26K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable BeiGene: Sold 2,181 at $251.95 on Sep 14, 2020 · $550K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable BeiGene: Sold 3,157 at $250.71 on Sep 14, 2020 · $791K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable BeiGene: Sold 6,478 at $249.97 on Sep 14, 2020 · $1.6M (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable BeiGene: Sold 1,681 at $248.93 on Sep 14, 2020 · $418K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable BeiGene: Sold 400 at $247.46 on Sep 14, 2020 · $99K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable BeiGene: Sold 300 at $191.23 on Jun 29, 2020 · $57K | Filing · EDGAR |
| — | — | — | Notice not machine-readable BeiGene: Sold 453 at $170.84 on Jun 8, 2020 · $77K | Filing · EDGAR |
| — | — | — | Notice not machine-readable BeiGene: Sold 400 at $198.93 on Nov 18, 2019 · $80K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable BeiGene: Sold 200 at $197.55 on Nov 18, 2019 · $40K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable BeiGene: Sold 200 at $196.63 on Nov 18, 2019 · $39K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable BeiGene: Sold 5,633 at $195.57 on Nov 18, 2019 · $1.1M (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable BeiGene: Sold 8,156 at $194.62 on Nov 18, 2019 · $1.6M (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable BeiGene: Sold 6,944 at $193.60 on Nov 18, 2019 · $1.3M (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable BeiGene: Sold 2,311 at $192.63 on Nov 18, 2019 · $445K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable BeiGene: Sold 1,156 at $191.80 on Nov 18, 2019 · $222K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable BeiGene: Sold 5,876 at $9.47 on Jun 27, 2019 · $56K | Filing · EDGAR |
| — | — | — | Notice not machine-readable BeiGene: Sold 23,200 at $130.21 on May 21, 2019 · $3M (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable BeiGene: Sold 1,800 at $130.01 on May 6, 2019 · $234K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable BeiGene: Sold 900 at $164.36 on Mar 19, 2018 · $148K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable BeiGene: Sold 4,636 at $163.48 on Mar 19, 2018 · $758K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable BeiGene: Sold 5,133 at $162.79 on Mar 19, 2018 · $836K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable BeiGene: Sold 3,141 at $161.62 on Mar 19, 2018 · $508K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable BeiGene: Sold 9,618 at $160.60 on Mar 19, 2018 · $1.5M (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable BeiGene: Sold 5,200 at $159.62 on Mar 19, 2018 · $830K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable BeiGene: Sold 500 at $158.45 on Mar 19, 2018 · $79K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable BeiGene: Sold 400 at $157.98 on Mar 16, 2018 · $63K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable BeiGene: Sold 7,264 at $157.41 on Mar 16, 2018 · $1.1M (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable BeiGene: Sold 2,208 at $156.75 on Mar 16, 2018 · $346K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable BeiGene: Sold 1,000 at $154.95 on Mar 16, 2018 · $155K (10b5-1 plan) | Filing · EDGAR |
Every transaction, by company
Each Form 3, 4 and 5 transaction in plain words, newest first.
How these figures work
Values are shares times the price each filing states; grants, exercises and gifts usually state no price. Held after is what the filing reports was held once the transaction was done, directly or through the named holder.
BeiGene CFO & Chief Strategy Officer · filings 2016 to 2021 · sold $48.8M · bought $120K
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Jun 28, 2021 | Open-market or private sale | −446 | $365.00 | $163K | 0 direct | Filing · EDGAR |
| Jun 18, 2021 | Open-market or private sale | −486 | $325.89 | $158K | 0 direct | Filing · EDGAR |
| Jun 7, 2021 | Open-market or private sale | −650 | $354.16 | $230K | 0 direct | Filing · EDGAR |
| Jan 15, 2021 | Option or RSU exercised or converted | +12,600 | $6.50 | $82K | 12,600 direct | Filing · EDGAR |
| Jan 15, 2021 | Sale under a 10b5-1 plan | −6,994 | $344.38 | $2.4M | 5,606 direct | Filing · EDGAR |
| Jan 15, 2021 | Sale under a 10b5-1 plan | −5,606 | $345.54 | $1.9M | 0 direct | Filing · EDGAR |
| Jan 15, 2021 | Option or RSU exercised or converted Stock Option (Right to Buy) | −163,800 | 649,000 direct | Filing · EDGAR | ||
| Jan 14, 2021 | Option or RSU exercised or converted | +1,400 | $6.50 | $9K | 1,400 direct | Filing · EDGAR |
| Jan 14, 2021 | Sale under a 10b5-1 plan | −1,100 | $344.28 | $379K | 300 direct | Filing · EDGAR |
| Jan 14, 2021 | Sale under a 10b5-1 plan | −300 | $345.15 | $104K | 0 direct | Filing · EDGAR |
| Jan 14, 2021 | Option or RSU exercised or converted Stock Option (Right to Buy) | −18,200 | 812,800 direct | Filing · EDGAR | ||
| Dec 14, 2020 | Option or RSU exercised or converted | +1,405,300 | $0.50 | $703K | 1,573,715 direct | Filing · EDGAR |
| Dec 14, 2020 | Option or RSU exercised or converted | +91,900 | $6.50 | $597K | 91,900 direct | Filing · EDGAR |
| Dec 14, 2020 | Open-market or private sale | −4,100 | $225.24 | $923K | 87,800 direct | Filing · EDGAR |
| Dec 14, 2020 | Open-market or private sale | −6,203 | $226.40 | $1.4M | 81,597 direct | Filing · EDGAR |
| Dec 14, 2020 | Open-market or private sale | −15,062 | $227.08 | $3.4M | 66,535 direct | Filing · EDGAR |
| Dec 14, 2020 | Open-market or private sale | −7,500 | $227.72 | $1.7M | 59,035 direct | Filing · EDGAR |
| Dec 14, 2020 | Open-market or private sale | −400 | $228.10 | $91K | 58,635 direct | Filing · EDGAR |
| Dec 14, 2020 | Open-market or private sale | −5,885 | $228.23 | $1.3M | 52,750 direct | Filing · EDGAR |
| Dec 14, 2020 | Open-market or private sale | −9,752 | $229.18 | $2.2M | 42,998 direct | Filing · EDGAR |
| Dec 14, 2020 | Open-market or private sale | −24,842 | $230.51 | $5.7M | 18,156 direct | Filing · EDGAR |
| Dec 14, 2020 | Open-market or private sale | −17,456 | $231.11 | $4M | 700 direct | Filing · EDGAR |
| Dec 14, 2020 | Open-market or private sale | −700 | $232.19 | $163K | 0 direct | Filing · EDGAR |
| Dec 14, 2020 | Option or RSU exercised or converted Stock Option (Right to Buy) | −2,600,000 | 831,000 direct | Filing · EDGAR | ||
| Oct 5, 2020 | Option or RSU exercised or converted | +14,000 | $6.50 | $91K | 14,000 direct | Filing · EDGAR |
| Oct 5, 2020 | Sale under a 10b5-1 plan | −817 | $293.26 | $240K | 13,183 direct | Filing · EDGAR |
| Oct 5, 2020 | Sale under a 10b5-1 plan | −1,415 | $294.92 | $417K | 11,768 direct | Filing · EDGAR |
| Oct 5, 2020 | Sale under a 10b5-1 plan | −568 | $295.73 | $168K | 11,200 direct | Filing · EDGAR |
| Oct 5, 2020 | Sale under a 10b5-1 plan | −500 | $296.47 | $148K | 10,700 direct | Filing · EDGAR |
| Oct 5, 2020 | Sale under a 10b5-1 plan | −1,200 | $297.98 | $358K | 9,500 direct | Filing · EDGAR |
| Oct 5, 2020 | Sale under a 10b5-1 plan | −1,000 | $298.97 | $299K | 8,500 direct | Filing · EDGAR |
| Oct 5, 2020 | Sale under a 10b5-1 plan | −2,001 | $300.08 | $600K | 6,499 direct | Filing · EDGAR |
| Oct 5, 2020 | Sale under a 10b5-1 plan | −1,499 | $300.88 | $451K | 5,000 direct | Filing · EDGAR |
| Oct 5, 2020 | Sale under a 10b5-1 plan | −2,831 | $302.11 | $855K | 2,169 direct | Filing · EDGAR |
| Oct 5, 2020 | Sale under a 10b5-1 plan | −1,869 | $303.24 | $567K | 300 direct | Filing · EDGAR |
| Oct 5, 2020 | Sale under a 10b5-1 plan | −300 | $304.15 | $91K | 0 direct | Filing · EDGAR |
| Oct 5, 2020 | Option or RSU exercised or converted Stock Option (Right to Buy) | −182,000 | 3,431,000 direct | Filing · EDGAR | ||
| Sep 14, 2020 | Option or RSU exercised or converted | +14,000 | $6.50 | $91K | 14,000 direct | Filing · EDGAR |
| Sep 14, 2020 | Sale under a 10b5-1 plan | −400 | $247.46 | $99K | 13,600 direct | Filing · EDGAR |
| Sep 14, 2020 | Sale under a 10b5-1 plan | −1,681 | $248.93 | $418K | 11,919 direct | Filing · EDGAR |
| Sep 14, 2020 | Sale under a 10b5-1 plan | −6,478 | $249.97 | $1.6M | 5,441 direct | Filing · EDGAR |
| Sep 14, 2020 | Sale under a 10b5-1 plan | −3,157 | $250.71 | $791K | 2,284 direct | Filing · EDGAR |
| Sep 14, 2020 | Sale under a 10b5-1 plan | −2,181 | $251.95 | $550K | 103 direct | Filing · EDGAR |
| Sep 14, 2020 | Sale under a 10b5-1 plan | −103 | $252.59 | $26K | 0 direct | Filing · EDGAR |
| Sep 14, 2020 | Option or RSU exercised or converted Stock Option (Right to Buy) | −182,000 | 3,613,000 direct | Filing · EDGAR | ||
| Jun 29, 2020 | Open-market or private sale | −300 | $191.23 | $57K | 0 direct | Filing · EDGAR |
| Jun 17, 2020 | Grant or award from the company | +55,887 | 172,315 direct | Filing · EDGAR | ||
| Jun 17, 2020 | Grant or award from the company Share Option (Right to Buy) | +315,341 | 315,341 direct | Filing · EDGAR | ||
| Jun 8, 2020 | Open-market or private sale | −453 | $170.84 | $77K | 0 direct | Filing · EDGAR |
| Nov 18, 2019 | Option or RSU exercised or converted | +25,000 | $6.50 | $163K | 25,000 direct | Filing · EDGAR |
| Nov 18, 2019 | Sale under a 10b5-1 plan | −1,156 | $191.80 | $222K | 23,844 direct | Filing · EDGAR |
| Nov 18, 2019 | Sale under a 10b5-1 plan | −2,311 | $192.63 | $445K | 21,533 direct | Filing · EDGAR |
| Nov 18, 2019 | Sale under a 10b5-1 plan | −6,944 | $193.60 | $1.3M | 14,589 direct | Filing · EDGAR |
| Nov 18, 2019 | Sale under a 10b5-1 plan | −8,156 | $194.62 | $1.6M | 6,433 direct | Filing · EDGAR |
| Nov 18, 2019 | Sale under a 10b5-1 plan | −5,633 | $195.57 | $1.1M | 800 direct | Filing · EDGAR |
| Nov 18, 2019 | Sale under a 10b5-1 plan | −200 | $196.63 | $39K | 600 direct | Filing · EDGAR |
| Nov 18, 2019 | Sale under a 10b5-1 plan | −200 | $197.55 | $40K | 400 direct | Filing · EDGAR |
| Nov 18, 2019 | Sale under a 10b5-1 plan | −400 | $198.93 | $80K | 0 direct | Filing · EDGAR |
| Nov 18, 2019 | Option or RSU exercised or converted Stock Option (Right to Buy) | −325,000 | 3,795,000 direct | Filing · EDGAR | ||
| Jun 27, 2019 | Open-market or private sale | −5,876 | $9.47 | $56K | 122,317 direct | Filing · EDGAR |
28 earlier transactions are in the filing list below.
All 23 Forms 3, 4, 5 and 144
| Filed | Form | Company | Links |
|---|---|---|---|
| Oct 29, 2026 | Form 3 | Bambusa Therapeutics BBTX | Filing · EDGAR |
| Jun 30, 2021 | Form 4 | BeiGene | Filing · EDGAR |
| Jun 21, 2021 | Form 4 | BeiGene | Filing · EDGAR |
| Jun 9, 2021 | Form 4 | BeiGene | Filing · EDGAR |
| Jan 19, 2021 | Form 4 | BeiGene | Filing · EDGAR |
| Dec 16, 2020 | Form 4 | BeiGene | Filing · EDGAR |
| Oct 7, 2020 | Form 4 | BeiGene | Filing · EDGAR |
| Sep 16, 2020 | Form 4 | BeiGene | Filing · EDGAR |
| Jul 1, 2020 | Form 4 | BeiGene | Filing · EDGAR |
| Jun 19, 2020 | Form 4 | BeiGene | Filing · EDGAR |
| Jun 10, 2020 | Form 4 | BeiGene | Filing · EDGAR |
| Nov 20, 2019 | Form 4 | BeiGene | Filing · EDGAR |
| Jul 1, 2019 | Form 4 | BeiGene | Filing · EDGAR |
| Jun 7, 2019 | Form 4 | BeiGene | Filing · EDGAR |
| May 22, 2019 | Form 4 | BeiGene | Filing · EDGAR |
| May 8, 2019 | Form 4 | BeiGene | Filing · EDGAR |
| Jun 28, 2018 | Form 4 | BeiGene | Filing · EDGAR |
| Mar 20, 2018 | Form 4 | BeiGene | Filing · EDGAR |
| Jun 29, 2017 | Form 4/A | BeiGene | Filing · EDGAR |
| Jun 29, 2017 | Form 4 | BeiGene | Filing · EDGAR |
| Nov 18, 2016 | Form 4 | BeiGene | Filing · EDGAR |
| Feb 9, 2016 | Form 4 | BeiGene | Filing · EDGAR |
| Feb 2, 2016 | Form 3 | BeiGene | Filing · EDGAR |
Every figure is as filed with the SEC on Forms 3, 4, 5 and 144. Holdings are the amounts reported after each person's latest filing at each company and can be out of date. Matching a Form 144 notice to Form 4 sales is SEC Tracker's inference from owner, company, dates and share counts, not something the filings state. Not investment advice. Not affiliated with the U.S. SEC.